Initial Treatment of Differentiated Thyroid Carcinoma

Reviews in Endocrine and Metabolic Disorders

Volumn 1, Issue 3, 2000, Pages 139-145

  Haugen, Bryan R ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Differentiated thyroid carcinoma treatment; Levothyroxine therapy; Radioiodine; Staging; Thyroid carcinoma

Indexed keywords

RADIOACTIVE IODINE; THYROXINE;

CANCER STAGING; HUMAN; PATHOLOGY; REVIEW; RISK FACTOR; THYROID TUMOR; THYROIDECTOMY; TUMOR RECURRENCE;

HUMANS; IODINE RADIOISOTOPES; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RISK FACTORS; THYROID NEOPLASMS; THYROIDECTOMY; THYROXINE;

EID: 0034173329     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010066728437     Document Type: Article

References (37)

1. Dulgeroff AJ, Hershamn JM. Medical therapy for differentiated thyroid carcinoma. Endocrine Reviews 1994;15:500-515.
2. Sherman SI, Brierley J, Sperling M, et al. Prospective multicenter study of thyroid carcinoma treatment. Cancer 1998;83:1012-1021.
3. Brierley JD, Panzarella T, Tsang RW, Gospodarowicz MK, O'Sullivan B. A comparison of different staging systems predictability of patient outcome. Cancer 1997;79:2414-2423.
4. Samaan NA, Maheshwari YK, Nader S, et al. Impact of therapy for differentiated carcinoma of the thyroid: An analysis of 706 cases. Journal of Clinical Endocrinology and Metabolism 1983;56:1131-1138.
5. Tubiana M, Schlumberger M, Rougier P, et al. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 1985;55:794-804.
6. Simpson WJ, McKinney SE, Carruthers JS, Gospodarowicz MK, Sutcliffe SB, Panzarella T. Papillary and follicular thyroid cancer. American Journal of Medicine 1987;479-488.
7. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 1990;71:414-424.
8. Samaan NA, Schultz PN, Hickey RC, et al. The results of various modalities of treatment of well differentiated thyroid carcinoma: A retrospective review of 1599 patients. Journal of Clinical Endocrinology and Metabolism 1992;75:714-720.
9. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. American Journal of Medicine 1994;97:418-428.
10. Tsang RW, Brierley J, Simpson WJ, Panzarella T, Gospodarowicz MK, Sutcliffe SB. The effects of surgery, radioiodein, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 1998;82:375-388.
11. Kuijpens JL, Hansen B, Hamming JF, Ribot JG, Haak HR, Coebergh JWW. Trends in treatment and long-term survival of thyroid cancer in Southeastern Netherlands, 1960-1992. Eur J Can 1998;34:1235-1241.
12. Cady B. Beyond risk groups - A new look at differentiated thyroid cancer. Surgery 1998;124:947-957.
13. McConahey WM, Hay ID, Woolner LB, VanHeerden JA, Taylor WF. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970 initial manifestations, pathologic findings, therapy, and outcome. Mayo Clinic Proceedings 1986;61:978-996.
14. Woolner LB, Lemmon ML, Beahrs OH, Black BM, Keating FR. Occult papillary carcinoma of the thyroid gland: A study of 140 cases observed in a 30-year period. Journal of Clinical Endocrinology and Metabolism 1960;20:89-105.
15. Woolner LB, Beahrs OH, Black BM, McConahey WM, Keating FR. Classification and prognosis of thyroid carcinoma. Am J Surg 1961;102:354-387.
16. Tollefsen HR, DeCosse JJ, Hutter RVP. Papillary carcinoma of the thyroid: A clinical and pathological study of 70 fatal cases. Cancer 1964;17:1035-1044.
17. Crile G. Survival of patients with carcinoma of the thyroid after conservative operations. Am J Surg 1964;108:862-866.
18. Varma VM, Beierwaltes WH, Nofal MM, Nishiyama RH, Copp JE. Treatment of thyroid cancer: Death rates after surgery and after surgery followed by sodium iodide 1131. JAMA 1970;214:1437-1442.
19. Attie JN, Khafif RA, Steckler RM. Elective neck dissection in papillary carcinoma of the thyroid. Am J Surg 1971;122:464-471.
20. Cady B, Sedgwick CE, Meissner WA, Bookwalter JR, Romagosa V, Werber J. Changing clinical, pathologic, therapeutic, and survival patterns in differentiated thyroid carcinoma. Annals of Surgery 1976;184:541-553.
21. Mazzaferri EL, Young RL, Oertel JE, Kemmerer WT, Page CP. Papillary thyroid carcinoma The impact of therapy in 576 patients. Medicine: 1977;56:171-196.
22. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: A 10 year follow-up report on the impact of therapy in 576 patients. American Journal of Medicine 1981;70:511-518.
23. Crile G, Antunez AR, Esselstyn CB, Hawk WA, Skillern PG. The advantages of subtotal thyroidectomy and suppression of TSH in the primary treatment of papillary carcinoma of the thyroid. Cancer 1985;55:2691-2697.
24. Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J. Papillary carcinoma of the thyroid: A clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer 1985;55:805-828.
25. Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz MK, Sutcliffe SB. Papillary and follicular thyroid cancer. Impact of treatment in 1578 patients. International Journal of Radiation Oncology, Biology and Physics 1988;14:1063-1075.
26. Taylor T, Specker B, Robbins J, et al. Outcome after treatment of high-risk papillary and non-Hurthle cell follicular thyroid carcinoma. Annals of Internal Medicine 1998;129:622-627.
27. Hay ID, Grant CS, Bergstralh EJ, Thompson GS, van Heerden JA, Goellner JR. Unilateral total lobectomy is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery 1998;124:958-964.
28. Tubiana M, Haddad E, Schlumberger M, Hill C, Rougier P, Sarrazin D. External radiotherapy in thyroid cancers. Cancer 1985;55:2062-2071.
29. Esik O, Nemeth G, Eller J. Prophylactic external irradiation in differentiated thyroid cancer. A retrospective study over a 30-year observation period. Oncology 1994;51:372-379.
30. Farahati J, Reiners C, Stuschke M, et al. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). Cancer 1996;77:172-180.
31. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988;104:947-953.
32. Shaha AR, Shah JP, Loree TR. Low risk differentiated thyroid cancer the need for selective treatment. Annals of Surgical Oncology 1997;4:328-333.
33. Solomon BL, Wartofsky L, Burman KD. Current trends in the management of differentiated papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 1996;81:333-339.
34. Pinchera A, Martino E, Bartalena L, Pacchiarotti A, Aghini-Lombardi F, Grasso L. Adequacy of TSH suppression by L-thyroxine administration in thyroid cancer patients after total thyroidectomy. Journal of Endocrinological Investigation 1986;9:77-88.
35. Burmeister LA, Goumaz MO, Mariash GA, Oppenheimer JO. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism 1992;75:344-350.
36. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism 1996;81:4318-4323.
37. Cooper DS, Specker B, Ho M, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer. Results from the national thyroid cancer treatment cooperative registry. Thyroid 1998;8:737-744.